Clinical Trial

Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery

Completed
View on ClinicalTrials.gov →
Summary
Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after surgery.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-13; most recent amendment 2026-06-28.
Status change: Recruiting → Completed 2026-06-28
Status change: Not Yet Recruiting → Recruiting 2025-06-23
Trial Details
NCT Number NCT06981754
Lead Sponsor Beijing Tiantan Hospital
Collaborators: Beijing Ditan Hospital, Beijing Electric Power Hospital
Conditions Postoperative Nausea and Vomiting, Dexamethasone Palmitate, Minimally Invasive Endoscopic Procedures
Enrollment 588 participants
Start Date 2025-06-17
Primary Completion 2026-04-03 (estimated)
Study Completion 2026-05-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-01